We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Algeta Announces first US Patient Randomized in ALSYMPCA Phase III Study

News   Dec 16, 2009

 
Algeta Announces first US Patient Randomized in ALSYMPCA Phase III Study
 
 
Advertisement
 

RELATED ARTICLES

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

Rapid Test for COVID-19 Shows Improved Sensitivity

News

A CRISPR-based test developed at MIT and the Broad Institute can detect nearly as many cases as the standard COVID-19 diagnostic.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE